← All trials
NCT03224104
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2018
- Primary completion
- Aug 31, 2020
- Completion date
- Aug 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 81
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- University of LilleOverall official - principal investigator
- Adastra PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.